Qiagen N.V. (QGEN)
NYSE: QGEN · Real-Time Price · USD
40.72
-0.72 (-1.74%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Qiagen Revenue
In the year 2024, Qiagen had annual revenue of $1.98B with 0.66% growth. Qiagen had revenue of $521.20M in the quarter ending December 31, 2024, with 2.36% growth.
Revenue (ttm)
$1.98B
Revenue Growth
+0.66%
P/S Ratio
4.45
Revenue / Employee
$331,526
Employees
5,967
Market Cap
8.80B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.98B | 12.90M | 0.66% |
Dec 31, 2023 | 1.97B | -176.21M | -8.23% |
Dec 31, 2022 | 2.14B | -110.14M | -4.89% |
Dec 31, 2021 | 2.25B | 381.31M | 20.39% |
Dec 31, 2020 | 1.87B | 343.92M | 22.53% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
QGEN News
- 4 days ago - QIAGEN Advancing Plans to Launch Three New Sample Preparation Instruments by 2026 to Improve Lab Automation - Business Wire
- 10 days ago - QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast - Business Wire
- 12 days ago - QIAGEN Delivers Strong Preliminary Q1 2025 Results Exceeding Outlook and Raises Full-Year 2025 Adjusted EPS Outlook - Business Wire
- 18 days ago - QIAGEN Launches QIAprep& Plasmodium Kit to Strengthen Malaria Research and Surveillance Efforts - Business Wire
- 19 days ago - QIAGEN Announces Form 20-F Annual Report Filing for 2024 Results - Business Wire
- 6 weeks ago - QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio - Business Wire
- 6 weeks ago - QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing - Business Wire
- 7 weeks ago - Qiagen N.V.: Some Clarity Needed Before Buying The Dip - Seeking Alpha